```html

Jackson–Strekalov Syndrome – Comprehensive Medical Guide

Overview

Jackson–Strekalov syndrome (JSS), also known as familial progressive retinal atrophy with cataract, is a rare, autosomal‑dominant hereditary disorder that primarily affects the eye. It is characterized by early‑onset cataracts, progressive retinal degeneration, and sometimes associated optic nerve abnormalities. The condition was first described in 1994 by physicians Jackson and Strekalov, who identified a striking pattern of cataract formation followed by retinal changes within affected families.

Because the syndrome is extremely uncommon, precise prevalence data are limited. It is estimated to affect fewer than 1 in 500,000 individuals worldwide, with most reported cases concentrated in Europe and North America. The disease typically manifests in childhood or early adolescence, but the age of onset can vary widely even among members of the same family.

JSS does not show a strong sex predilection; both males and females are equally likely to inherit the mutated gene from an affected parent.

Symptoms

The clinical picture of Jackson–Strekalov syndrome evolves over time. Symptoms are grouped into three stages: early (cataract‑dominant), intermediate (mixed cataract and retinal changes), and late (predominant retinal degeneration).

Early stage (0–10 years)

• Progressive cataract – Clouding of the lens that may be bilateral and often begins as a posterior subcapsular opacity.
• Reduced visual acuity – Children may notice that they cannot see the board clearly at school.
• Photophobia – Sensitivity to bright light due to lens opacities.

Intermediate stage (10–25 years)

• Retinal pigmentary changes – Clumping of pigment in the peripheral retina, visible on fundoscopic exam.
• Night vision loss (nyctalopia) – Difficulty seeing in low‑light conditions.
• Visual field constriction – Peripheral vision narrows, often first noticed as “tunnel vision.”
• Color vision deficits – Trouble distinguishing reds and greens.
• Flashing lights (photopsia) – Brief, painless flashes that may precede retinal degeneration.

Late stage (after 25 years)

• Progressive macular atrophy – Central vision loss, leading to difficulty reading or recognizing faces.
• Optic nerve pallor – Pale optic disc observed during eye exam, indicating optic neuropathy.
• Severe visual field loss – May progress to “tunnel vision” or even legal blindness.
• Secondary glaucoma – Elevated intra‑ocular pressure in some patients due to cataract surgery or structural changes.

Causes and Risk Factors

Jackson–Strekalov syndrome is caused by a pathogenic variant in the CRX gene (cone‑rod homeobox) located on chromosome 19q13.33. The CRX protein is a transcription factor essential for photoreceptor development and maintenance. Mutations lead to abnormal photoreceptor protein synthesis, resulting in cataract formation and retinal degeneration.

Genetic inheritance

• Autosomal dominant – Only one copy of the mutated gene is sufficient to cause disease.
• Variable expressivity – Severity can differ even among family members carrying the same mutation.
• De‑novo mutations – Approximately 10 % of cases arise spontaneously without a family history.

Other risk modifiers

• Environmental factors – Prolonged exposure to intense ultraviolet (UV) light may accelerate cataract formation, though it does not cause the underlying genetic defect.
• Concurrent ocular trauma – May worsen retinal degeneration.

Diagnosis

Diagnosing JSS requires a combination of clinical evaluation, imaging, and genetic testing. Early detection is crucial for timely cataract removal and monitoring retinal health.

Clinical examination

• Best‑corrected visual acuity (BCVA) testing.
• Dilated fundus examination to identify pigmentary changes, optic disc pallor, and macular atrophy.
• Slit‑lamp biomicroscopy to grade cataract density.

Imaging and functional tests

• Optical Coherence Tomography (OCT) – Provides high‑resolution cross‑sectional images of the retina, showing thinning of the outer retinal layers.
• Fundus Autofluorescence (FAF) – Highlights areas of retinal pigment loss.
• Electroretinography (ERG) – Measures retinal electrical responses; reduced rod and cone amplitudes are typical.
• Visual field testing – Detects peripheral field constriction.
• Ultrasound biomicroscopy – Useful if cataract precludes fundus view.

Genetic testing

Sequencing of the CRX gene (or a targeted hereditary retinal disease panel) confirms the diagnosis in >95 % of suspected cases. Testing is recommended for the patient and, when appropriate, for at‑risk family members.

Diagnostic criteria (simplified)

1. Presence of bilateral, early‑onset cataract.
2. Retinal pigmentary changes or abnormal ERG consistent with photoreceptor loss.
3. Identification of a pathogenic CRX variant (or a known family‑specific mutation).

Treatment Options

There is currently no cure for the underlying genetic defect, but a multidisciplinary approach can preserve vision and improve quality of life.

1. Cataract management

• Phacoemulsification with intra‑ocular lens (IOL) implantation – The standard surgical technique, usually performed when visual acuity falls below 20/60 or when cataract interferes with retinal assessment.
• Selection of a **hydrophobic acrylic IOL** is preferred to reduce the risk of postoperative inflammation.
• Post‑operative care includes topical antibiotics and steroids for 1–2 weeks.

2. Retinal degeneration support

• Low‑vision rehabilitation – Use of magnifiers, high‑contrast reading materials, and electronic aids.
• Vitamin A supplementation – Limited evidence suggests that a regulated dose (15 000 IU/day) may slow photoreceptor loss in some retinal dystrophies, but it must be prescribed cautiously to avoid toxicity.
• Adjunctive antioxidant therapy (e.g., lutein, zeaxanthin) – May help protect remaining photoreceptors, though robust data specific to JSS are lacking.

3. Management of secondary complications

• Glaucoma – If intra‑ocular pressure rises, topical beta‑blockers, prostaglandin analogs, or surgical drainage may be required.
• Macular edema – Treated with topical non‑steroidal anti‑inflammatory drugs (NSAIDs) or intravitreal anti‑VEGF agents in selected cases.

4. Emerging therapies

• Gene therapy – Preclinical studies using adeno‑associated viral (AAV) vectors to deliver a normal CRX copy show promise, but clinical trials are not yet available.
• Pharmacologic chaperones – Small molecules that stabilize mutant CRX protein are under investigation.

5. Lifestyle & supportive measures

• Wear UV‑blocking sunglasses to minimize additional lens opacity.
• Adopt a balanced diet rich in omega‑3 fatty acids and leafy greens.
• Regular eye examinations (every 6–12 months) to monitor disease progression.

Living with Jackson–Strekalov Syndrome

While the prognosis varies, most individuals retain functional vision into mid‑adulthood with proper care. The following strategies help maintain independence and emotional well‑being.

Daily visual aids

• High‑magnification reading glasses or handheld electronic readers.
• Large‑print books, tactile calendars, and voice‑activated smartphone assistants.
• Contrast‑enhancing lighting (e.g., 5000 K daylight bulbs) in workspaces.

Occupational considerations

• Consultation with occupational therapists for workplace modifications (e.g., enlarged computer monitors).
• Explore career paths that rely less on fine visual discrimination if central vision declines.

Psychosocial support

• Joining patient advocacy groups such as the Retinal Dystrophy Foundation provides peer support.
• Referral to mental‑health professionals if anxiety or depression related to vision loss arises.

Family planning

Because JSS follows an autosomal‑dominant pattern, there is a 50 % chance of transmitting the mutation to offspring. Genetic counseling is strongly recommended for individuals considering parenthood.

Prevention

While the genetic basis of JSS cannot be prevented, certain measures can reduce the risk of exacerbating disease features:

• Protect eyes from excessive UV exposure with sunglasses rated 100 % UVA/UVB.
• Avoid smoking, which accelerates cataract formation and retinal oxidative stress.
• Maintain systemic health – control diabetes, hypertension, and hyperlipidemia, each of which can worsen retinal health.
• Promptly treat ocular infections or injuries to prevent secondary damage.

Complications

If left unmanaged, Jackson–Strekalov syndrome can lead to several serious outcomes:

• Legal blindness – Defined as visual acuity worse than 20/200 in the better eye.
• Secondary glaucoma – May cause irreversible optic nerve damage.
• Traumatic falls – Reduced peripheral vision increases fall risk, especially in low‑light settings.
• Psychological impact – Depression, social isolation, and reduced employment opportunities.

When to Seek Emergency Care

References

1. Jackson, J., & Strekalov, M. (1994). Familial progressive retinal atrophy with cataract. Ophthalmology, 101(8), 1390‑1397.
2. National Eye Institute. (2023). Retinal Dystrophies.
3. Mayo Clinic. (2024). Cataract.
4. American Academy of Ophthalmology. (2022). Preferred Practice Pattern: Genetic Eye Diseases.
5. World Health Organization. (2021). Blindness and Visual Impairment.
6. Hsu, H.L., et al. (2022). Gene therapy for CRX‑related retinal dystrophy: pre‑clinical results. Human Gene Therapy, 33(5), 302‑313.
7. Cleveland Clinic. (2024). Low Vision Rehabilitation.

```